Apogee Therapeutics IncNASDAQ:APGE
- LAST PRICE49.1000
- TODAY'S CHANGE (%)-1.5200 (-3.0028%)
- Bid / Lots19.7600/ 2
- Ask / Lots51.0000/ 1
- Open / Previous Close50.4800 / 50.6200
- Day Range
- 52 Week Range
- Volume269,319
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APGE |
|---|---|---|
| 09:32 ET | 2078 | 50.48 |
| 09:39 ET | 600 | 50.925 |
| 09:41 ET | 100 | 51.3427 |
| 09:43 ET | 316 | 50.985 |
| 09:45 ET | 928 | 51.3 |
| 09:50 ET | 5300 | 50.975 |
| 09:52 ET | 4988 | 50.88 |
| 09:54 ET | 600 | 50.97 |
| 09:56 ET | 11263 | 51.37 |
| 09:57 ET | 6654 | 51.34 |
| 09:59 ET | 1200 | 51.22 |
| 10:01 ET | 500 | 51.05 |
| 10:03 ET | 1108 | 51.085 |
| 10:08 ET | 100 | 50.94 |
| 10:10 ET | 316 | 50.795 |
| 10:14 ET | 200 | 50.55 |
| 10:15 ET | 600 | 50.725 |
| 10:17 ET | 100 | 50.55 |
| 10:19 ET | 100 | 50.51 |
| 10:21 ET | 3300 | 50.81 |
| 10:26 ET | 300 | 50.46 |
| 10:28 ET | 700 | 50.97 |
| 10:30 ET | 200 | 51.02 |
| 10:33 ET | 400 | 51.12 |
| 10:35 ET | 400 | 51.11 |
| 10:37 ET | 800 | 50.82 |
| 10:39 ET | 100 | 50.74 |
| 10:42 ET | 400 | 50.59 |
| 10:44 ET | 500 | 50.61 |
| 10:46 ET | 800 | 50.58 |
| 10:48 ET | 100 | 50.51 |
| 10:50 ET | 600 | 50.41 |
| 10:51 ET | 100 | 50.45 |
| 10:55 ET | 100 | 50.42 |
| 10:57 ET | 400 | 50.7 |
| 11:02 ET | 1200 | 50.3101 |
| 11:04 ET | 698 | 50.27 |
| 11:06 ET | 100 | 50.415 |
| 11:11 ET | 613 | 50.32 |
| 11:15 ET | 100 | 50.35 |
| 11:18 ET | 2747 | 49.9 |
| 11:20 ET | 880 | 49.97 |
| 11:22 ET | 1186 | 49.7425 |
| 11:24 ET | 600 | 49.7273 |
| 11:26 ET | 100 | 49.63 |
| 11:27 ET | 200 | 49.58 |
| 11:29 ET | 200 | 49.665 |
| 11:31 ET | 1450 | 49.46 |
| 11:33 ET | 200 | 49.69 |
| 11:36 ET | 200 | 49.46 |
| 11:38 ET | 100 | 49.58 |
| 11:40 ET | 200 | 49.385 |
| 11:42 ET | 306 | 49.58 |
| 11:44 ET | 100 | 49.625 |
| 11:45 ET | 200 | 49.675 |
| 11:47 ET | 800 | 49.4 |
| 11:51 ET | 100 | 49.23 |
| 11:56 ET | 600 | 49.12 |
| 11:58 ET | 2500 | 49.22 |
| 12:02 ET | 100 | 48.96 |
| 12:05 ET | 700 | 48.93 |
| 12:12 ET | 100 | 49 |
| 12:14 ET | 470 | 49.01 |
| 12:18 ET | 300 | 49.09 |
| 12:21 ET | 500 | 49.03 |
| 12:27 ET | 100 | 49.0275 |
| 12:30 ET | 100 | 48.93 |
| 12:32 ET | 900 | 48.98 |
| 12:34 ET | 2708 | 49.07 |
| 12:36 ET | 100 | 49.105 |
| 12:38 ET | 610 | 49.03 |
| 12:39 ET | 100 | 49.12 |
| 12:43 ET | 8131 | 49.285 |
| 12:45 ET | 947 | 49.67 |
| 12:50 ET | 100 | 49.795 |
| 12:52 ET | 800 | 50.08 |
| 12:57 ET | 100 | 50.13 |
| 12:59 ET | 400 | 50.015 |
| 01:01 ET | 21881 | 49.81 |
| 01:08 ET | 500 | 49.74 |
| 01:10 ET | 100 | 49.77 |
| 01:14 ET | 500 | 49.695 |
| 01:15 ET | 1000 | 49.595 |
| 01:17 ET | 1815 | 49.58 |
| 01:19 ET | 4000 | 49.75 |
| 01:21 ET | 1600 | 49.86 |
| 01:24 ET | 800 | 49.81 |
| 01:26 ET | 200 | 49.81 |
| 01:28 ET | 300 | 49.73 |
| 01:30 ET | 600 | 49.68 |
| 01:32 ET | 100 | 49.76 |
| 01:33 ET | 100 | 49.755 |
| 01:35 ET | 500 | 49.725 |
| 01:39 ET | 200 | 49.72 |
| 01:44 ET | 100 | 49.75 |
| 01:48 ET | 700 | 49.85 |
| 01:51 ET | 200 | 49.86 |
| 01:53 ET | 100 | 49.8 |
| 01:55 ET | 705 | 49.95 |
| 01:57 ET | 500 | 49.955 |
| 02:00 ET | 200 | 50 |
| 02:02 ET | 500 | 49.87 |
| 02:09 ET | 100 | 49.915 |
| 02:11 ET | 100 | 49.91 |
| 02:15 ET | 300 | 49.89 |
| 02:20 ET | 100 | 49.9075 |
| 02:22 ET | 100 | 49.97 |
| 02:24 ET | 200 | 49.97 |
| 02:29 ET | 600 | 50.03 |
| 02:31 ET | 200 | 50 |
| 02:33 ET | 800 | 49.89 |
| 02:36 ET | 100 | 49.98 |
| 02:40 ET | 188 | 49.9375 |
| 02:44 ET | 100 | 49.92 |
| 02:45 ET | 400 | 49.935 |
| 02:49 ET | 400 | 49.89 |
| 02:51 ET | 428 | 49.92 |
| 02:54 ET | 900 | 49.73 |
| 02:56 ET | 100 | 49.7875 |
| 03:02 ET | 500 | 49.89 |
| 03:05 ET | 400 | 49.73 |
| 03:16 ET | 100 | 49.915 |
| 03:18 ET | 100 | 49.83 |
| 03:20 ET | 100 | 49.83 |
| 03:21 ET | 300 | 49.8673 |
| 03:23 ET | 900 | 49.82 |
| 03:25 ET | 900 | 49.76 |
| 03:30 ET | 1105 | 49.67 |
| 03:32 ET | 400 | 49.55 |
| 03:34 ET | 400 | 49.475 |
| 03:36 ET | 500 | 49.45 |
| 03:38 ET | 700 | 49.39 |
| 03:41 ET | 300 | 49.13 |
| 03:43 ET | 500 | 49.13 |
| 03:45 ET | 100 | 49.125 |
| 03:48 ET | 400 | 49.11 |
| 03:50 ET | 500 | 49.05 |
| 03:52 ET | 500 | 48.995 |
| 03:54 ET | 2542 | 49.175 |
| 03:56 ET | 1021 | 49.325 |
| 03:57 ET | 1053 | 49.31 |
| 03:59 ET | 40479 | 49.1 |
Today
Sep 9, 2024
Press Release: Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow JonesApogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow Jones
Aug 19, 2024
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases, from 7:00AM ET on Monday Aug 19, 2024 by Dow Jones
7:00AM ET on Monday Aug 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Apogee Therapeutics Inc | 3.0B | -21.9x | --- |
MoonLake Immunotherapeutics | 3.0B | -56.4x | --- |
Xenon Pharmaceuticals Inc | 2.9B | -14.4x | --- |
SpringWorks Therapeutics Inc | 2.9B | -8.1x | --- |
Iovance Biotherapeutics Inc | 2.8B | -5.6x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Company Information
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Contact Information
- Headquarters
- 221 Crescent St. Building 17, Suite 102bWALTHAM, MA, United States 02453
- Phone
- 650-394-5230
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Mckenna
- Chief Executive Officer, Director
- Michael Henderson
- Chief Financial Officer
- Jane Henderson
- Chief Medical Officer
- Carl Dambkowski
- Independent Director
- Lisa Bollinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.25 |
Book Value | $7.86 |
P/E Ratio | -21.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
